arrow
P

Patrick Innamarato

h lee moffitt cancer center & research institute
H指数:13
被引数:1,096

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Feasibility of Manufacturing and Antitumor Activity of TIL for Advanced Endometrial Cancers

先进子宫内膜癌中TIL的制造可行性与抗肿瘤活性

2025-07-270
OA
Vgd1 and Vgd3 T cells are abundant gd T cells populations in high-grade serous ovarian carcinoma, non-small/small cell lung cancer, and show a heterogeneous g-chain usage
2024-05-010
PRE
Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers

用二聚体IgA靶向细胞内癌蛋白促进从细胞质中的排出和免疫介导的上皮癌控制

IMMUNITY
IF26.3
2023-11-0114
OA
Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients

新抗原特异性CD4肿瘤浸润淋巴细胞是转移性黑色素瘤患者过继细胞治疗产品中确定的有效效应物

2023-10-0610
OAAI
Sezary syndrome originates from heavily mutated hematopoietic progenitors

Sezary综合征起源于严重突变的造血祖细胞

2023-09-183
OAAI
Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy
2023-01-2331
OAAI
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
2022-10-1015
OA
Spontaneous class-switched antibody responses at endometrial cancer tumor bed drives superior patients' outcome
2022-05-010
PRE
Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T-cells
2022-05-010
OA
Early Recovery of Myeloid-Derived Suppressor Cells After Allogeneic Hematopoietic Transplant: Comparison of Post-Transplantation Cyclophosphamide to Standard Graft-Versus-Host Disease Prophylaxis

异基因造血移植后髓源性抑制细胞的早期恢复: 移植后环磷酰胺与标准移植物抗宿主病预防的比较

2022-04-018
OAAI
IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer
2022-03-0331
OA
TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures
IMMUNITY
IF26.3
2022-01-0188
OA